Human papillomavirus-associated diseases

Clinics in Dermatology

Volumn 32, Issue 2, 2014, Pages 253-258

  Grce, Magdalena ^a   Mravak Stipetić, Marinka ^b  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAPAPILLOMAVIRUS; ANUS NEOPLASMS; BETAPAPILLOMAVIRUS; CONDYLOMATA ACUMINATA; FEMALE; GAMMAPAPILLOMAVIRUS; GENITAL NEOPLASMS, FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MOUTH DISEASES; PAPILLOMA; PAPILLOMAVIRUS VACCINES; PENILE NEOPLASMS; RISK ASSESSMENT;

EID: 84894042565     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.10.006     Document Type: Note

References (63)

1. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human papillomaviruses 2007, 1-690. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer, World Health Organization, Lyon, France.
2. Kreimer A.R., Clifford G.M., Boyle P., et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475.
3. Secretan B., Straif K., Baan R., et al. A review of human carcinogens-part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009, 10:1033-1034.
4. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
5. Abramowitz L., Jacquard A.-C., Jaroud F., et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 2011, 129:433-439.
6. De Vuyst H., Clifford G.M., Nascimento M.C., et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
7. Miralles-Guri C., Bruni L., Cubilla A.L., et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009, 62:870-878.
8. Guily S., Lacau J., Jacquard A.C., et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France-the EDiTH VI study. J Clin Virol 2011, 51:100-104.
9. Zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009, 384:260-265.
10. Doorbar J., Quint W., Banks L., et al. The Biology and Life-Cycle of Human Papillomaviruses. Vaccine 2012, 30:F55-F70.
11. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses 1995, 1-436. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer, World Health Organization, Lyon, France.
12. Franceschi S., Muñoz N., Bosch X.F., et al. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996, 5:567-575.
13. Bouvard V., Baan R., Straif K., et al. A review of human carcinogens-part B: biological agents. Lancet Oncol 2009, 10:321-322.
14. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
15. Bruni L., Diaz M., Castellsagué X., et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-1799.
16. Grce M., Husnjak K., Skerlev M., et al. Detection and typing of human papillomaviruses by means of polymerase chain reaction and fragment length polymorphism in male genital lesions. Anticancer Res 2000, 20:2097-2102.
17. Scarbrough Lefebvre C.D., Van Kriekinge G., Gonçalves M.A., et al. Appraisal of the burden of genital warts from a healthcare and individual patient perspective. Public Health 2011, 125:464-475.
18. Giuliano A.R., Harris R., Sedjo R.L., et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002, 186:462-469.
19. Ostör A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993, 12:186-192.
20. Grce M., Husnjak K., Bozikov J., et al. Evaluation of genital human papillomavirus infections by polymerase chain reaction among Croatian women. Anticancer Res 2001, 21:579-584.
21. Clifford G.M., Smith J.S., Aguado T., et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89:101-105.
22. Muñoz N., Bosch F.X., De Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl J Med 2003, 348:518-527.
23. Bosch F.X., Lorincz A., Muñoz N., et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
24. De Sanjose S., Quint W., Alemany L., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
25. Schiffman M., Kjaer S.K. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 2003:14-19.
26. Kellokoski J., Syrjänen S., Syrjänen K., et al. Oral mucosal changes in women with genital HPV infection. J Oral Pathol Med 1990, 19:142-148.
27. Kellokoski J., Syrjänen S., Yliskoski M., et al. Dot blot hybridization in detection of human papillomavirus (HPV) infections in the oral cavity of women with genital HPV infections. Oral Microbiol Immunol 1992, 7:19-23.
28. Syrjanen S. Human papillomavirus infections and oral tumors. Med Microbiol Immunol 2003, 192:123-128.
29. Hormia M., Willberg J., Ruokonen H., et al. Marginal periodontium as a potential reservoir of human papillomavirus in oral mucosa. J Peridontol 2005, 76:358-363.
30. Bustos D.A., Grenón M.S., Benitez M., et al. Human papillomavirus infection in cyclosporin-induced gingival overgrowth in renal allograft recipients. J Periodontol 2001, 72:741-744.
31. Madeleine M.M., Anttila T., Schwartz S.M., et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 2007, 120:650-655.
32. Tezal M., Sullivan Nasca M., Stoler D.L., et al. Chronic periodontitis-human papillomavirus synergy in base of tongue cancers. Arch Otolaryngol Head Neck Surg 2009, 135:391-396.
33. Engels E.A., Biggar R.J., Hall H.I., et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008, 123:187-194.
34. D'Souza G., Agrawal Y., Halpern J., et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009, 199:1263-1269.
35. Smith E.M., Swarnavel S., Ritchie J.M., et al. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J 2007, 26:836-840.
36. Summersgill K.F., Smith E.M., Levy B.T., et al. Human papillomavirus in the oral cavities of children and adolescents. Oral Surg Oral Med Oral Pathol Oral Radiol 2001, 91:62-69.
37. Hansson B.G., Rosenquist K., Antonsson A., et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 2005, 125:1337-1344.
38. Schwartz S.M., Daling J.R., Madeleine M.M., et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998, 90:1626-1636.
39. Gillison M.L., Broutian T., Pickard R.K.L., et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012, 307:693-703.
40. D'Souza G., Fakhry C., Sugar E.A., et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007, 121:143-150.
41. Kreimer A.R., Alberg A.J., Daniel R., et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 2004, 189:686-698.
42. Hernandez B.Y., Wilkens L.R., Zhu X., et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008, 14:888-894.
43. Eversole L.R., Laipis P.J., Merrell P., et al. Demonstration of human papillomavirus DNA in oral condyloma acuminatum. J Oral Pathol 1987, 16:266-272.
44. Gassenmaier A., Hornstein O.P. Presence of human papillomavirus DNA in benign and precancerous oral leukoplakias and squamous cell carcinomas. Dermatologica 1988, 176:224-233.
45. Ostwald C., Rutsatz K., Schweder J., et al. Human papillomavirus 6/11, 16 and 18 in oral carcinomas and benign oral lesions. Med Microbiol Immunol 2003, 192:145-148.
46. Syrjänen S., Lodi G., von Bültzingslöwen I., et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 2011, 17:58-72.
47. Praetorius-Clausen F. Geographical aspects of oral focal epithelial hyperplasia. Pathol Microbiol (Basel) 1973, 39:204-213.
48. Said A.K., Leao J.C., Fedele S., et al. Focal epithelial hyperplasia-an update. J Oral Pathol Med 2013, 42:435-442.
49. Praetorius-Clausen F., Mogeltoft M., Roed-Petersen B., et al. Focal epithelial hyperplasia of the oral mucosa in a south-west Greenlandic population. Scand J Dent Res 1970, 78:287-294.
50. Bonagura V.R., Hatam L.J., Rosenthal D.W., et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS 2010, 118:455-470.
51. Szarka K., Tar I., Fehér E., et al. Progressive increase of human papillomavirus carriage rates in potentially malignant and malignant oral disorders with increasing malignant potential. Oral Microbiol Immunol 2009, 24:314-318.
52. Reichart P.A., Philipsen H.P. Oral erythroplakia-a review. Oral Oncol 2005, 41:551-561.
53. Nielsen H., Norrild B., Vedtofte P., et al. Human papillomavirus in oral premalignant lesions. Eur J Cancer B Oral Oncol 1996, 32:264-270.
54. Syrjänen K., Syrjänen S., Lamberg M., et al. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983, 12:418-424.
55. Arbyn M., de Sanjosé S., Saraiya M., et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012, 131:1969-1982.
56. Leemans C.R., Braakhuis B.J.M., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat Rev Cancer 2010, 11:9-22.
57. Orth G. Genetics and susceptibility to human papillomaviruses: epidermodysplasia verruciformis, a disease model. Bull Acad Natl Med 2010, 194:923-940. [discussion 941].
58. Lazarczyk M., Cassonnet P., Pons C., et al. The EVER Proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009, 73:348-370.
59. Grce M. Primary and secondary prevention of cervical cancer. Expert Rev Mol Diagn 2009, 9:851-857.
60. Charo R.A., Agosti J.M., Baden L.R., et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
61. Paavonen J., Naud P., Salmerón J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
62. Donovan B., Franklin N., Guy R., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11:39-44.
63. Corstjens P.L.A.M., Abrams W.R., Malamud D. Detecting viruses by using salivary diagnostics. J Am Dent Assoc 2012, 143:12S-18S.